Join
Live feed
·
PRReleasevia Quantisnow
HUTCHMED (China) Limited logo

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

ByQuantisnow·Wall Street's wire, on your screen.
HCM· HUTCHMED (China) Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HCM (HUTCHMED (China) Limited) and more on Quantisnow.